Under-the-Skin Tepezza Comparable to Infused Version in Key Study, Amgen Says

Why It Matters

A subcutaneous Tepezza could unlock new patient segments, boost sales, and strengthen Amgen’s position against emerging competitors in the thyroid eye disease space.

Key Takeaways

• Tepezza OBI achieved 77% response rate in trial
• Efficacy matched IV formulation, reducing proptosis 3.17 mm
• Subcutaneous delivery may broaden thyroid eye disease market
• Safety profile consistent with existing Tepezza data
• Competitor Viridian’s injection missed expectations, shares fell

Pulse Analysis

Tepezza (teprotumumab) became the first FDA‑approved therapy for thyroid eye disease (TED) after Amgen acquired Horizon Therapeutics for $28 billion in 2023. The autoimmune condition, linked to Graves’ disease, affects roughly 30,000 patients in the United States each year and can cause painful proptosis, double vision, and vision loss. Since launch, Tepezza has generated close to $2 billion in annual revenue, but sales have plateaued as infusion‑center logistics limit patient access. The drug’s blockbuster status makes any delivery innovation a strategic priority for Amgen. The well‑characterized mechanism of IGF‑1R inhibition reinforces its clinical credibility.

17 mm average improvement seen with the intravenous formulation. Safety signals remained consistent with the known profile, alleviating concerns about the hearing‑impairment signal that has lingered since launch. By removing the need for infusion chairs, the OBI could unlock a larger share of the TED market, improve adherence, and potentially reignite growth for Amgen’s flagship franchise. Moreover, the convenience of at‑home administration could reduce overall healthcare costs and improve patient quality of life.

Amgen’s move arrives as rivals scramble for more convenient delivery platforms. Viridian Therapeutics recently reported suboptimal Phase 3 results for its autoinjector elegrobart, sending its stock sharply lower, while its faster‑acting IV candidate veligrotug is still pending FDA review. The contrast underscores the advantage of a proven molecule paired with a new administration route. If regulatory clearance follows the upcoming medical‑conference presentation, Tepezza OBI could set a new standard for biologic eye‑disease treatments, pressuring competitors to accelerate their own subcutaneous pipelines. Analysts project that a successful subcutaneous launch could lift Amgen’s earnings guidance for the fiscal year.